Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heparin + sulfasalazine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
A combination of heparin, an anticoagulant used for thromboprophylaxis and treatment of thrombosis, and sulfasalazine, an anti-inflammatory drug used to treat inflammatory bowel diseases and rheumatoid arthritis. When used together, there may be an increased risk of bleeding, particularly following neuraxial anesthesia.
02
Targets
ATIII (Antithrombin III)SLCO2B1 (Organic anion transporting polypeptide 2B1)COX
Beyond the preview
Go deeper on heparin + sulfasalazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heparin + sulfasalazine.